USFDA nod to JnJ for Rybrevant, Chemotherapy combo for lung cancer treatment Anshika Mishra4 March 2024 5:09 PM ISTJohnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
Health Bulletin 04/ March/ 2024 Anshika Mishra4 March 2024 4:44 PM ISTHere the top health news for the day :Lady hardinge medical college to introduce new DNB and FNB courses soon Bringing good news to the postgraduate...
Johnson and Johnson gets USFDA approval for Rybrevant, chemotherapy combo for lung cancer treatment Ruchika Sharma2 March 2024 2:33 PM ISTRaritan: Johnson & Johnson has announced that following a priority review, the U.S. Food and Drug Administration (FDA) has approved RYBREVANT...
Merck gets positive EMA Committee opinion for Keytruda, chemotherapy combo for Resectable non-small cell lung cancer Ruchika Sharma26 Feb 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
New research offers hope to those affected by aggressive brain cancer Anshika Mishra20 Feb 2024 9:15 AM ISTNew research from the University of Sussex holds promise for extending life expectancy and enhancing treatment options for a common and aggressive...
Taxane-based chemotherapy in Asian breast cancer patients tied to skin changes, hair loss: Study Medha Baranwal20 Feb 2024 7:00 AM ISTSouth Korea: A recent study published in The Journal of Dermatology evaluated the effects of treatment regimens in Asian breast cancer (BC)...
AstraZeneca Tagrisso with chemotherapy approved in US for EGFR-mutated advanced lung cancer Ruchika Sharma17 Feb 2024 12:00 PM ISTTagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases.
Medical Bulletin 11/January/2024 Anshika Mishra11 Jan 2024 3:00 PM ISTHere are the top medical news of the day:Combining anti-tumor drugs with chemo may improve rare children’s cancer outcomesChildren who develop...
Combining anti tumor drugs with chemo may improve rare children's cancer outcomes Anshika Mishra11 Jan 2024 9:00 AM ISTChildren who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well...
Pfizer gets European Commission nod for Talzenna, Xtandi combo for prostate cancer Ruchika Sharma9 Jan 2024 10:00 AM ISTNew York: Pfizer Inc. has announced that the European Commission (EC) has approved TALZENNA (talazoparib), an oral poly ADP-ribose polymerase...
Jemperli plus Zejula combo significantly improved progression-free survival in primary advanced or recurrent endometrial cancer: GSK Ruchika Sharma20 Dec 2023 2:30 PM ISTLondon: GSK plc has announced positive headline results from a planned analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial...
